1
|
Małyszko J, Kozlowski L, Kozłowska K, Małyszko M, Małyszko J. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine? Oncotarget 2017; 8:66601-66619. [PMID: 29029541 PMCID: PMC5630441 DOI: 10.18632/oncotarget.18094] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 04/23/2017] [Indexed: 01/10/2023] Open
Abstract
A long time ago, the links between renal disease and malignancy were observed, however, quite recently, their importance was recognized and 'new' subspecialty in nephrology, namely 'onconephrology' was established. In the XXI century, patients with malignancy make up the most growing number of the subjects seen for nephrology consult and/or critical care nephrology services. A plethora of renal problems may be found in patients with malignancy. They may influence not only their short-term outcomes but also the adequate therapy of the underlying oncological problem. Thus, all these kidney-related issues pose an important challenge for both specialities: oncology and nephrology. In the review a spectrum of acute and chronic renal injury caused by the malignancy is presented as well as the associations between renal disease and cancer. Assessment of kidney function and its importance in patients with malignancy is also discussed as medical oncologists should check the appropriate dose of chemotherapeutic drugs in relation to the actual renal function before prescribing them to the patients. Moreover, effects of kidney function on outcomes in oncology is presented. In addition, nephrology services should better understand both the biology of malignancy with its treatment to become a valuable part treating team to yield the best possible outcome. It is important for nephrology services to be acknowledged and to take an active participation in care of oncology patients.
Collapse
Affiliation(s)
- Jolanta Małyszko
- Second Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland
| | - Leszek Kozlowski
- Department of Oncological Surgery, Ministry of Interior Affairs, Bialystok, Poland
| | - Klaudia Kozłowska
- Second Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland
| | - Maciej Małyszko
- Second Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland
| | - Jacek Małyszko
- First Department of Nephrology and Transplantology with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland
| |
Collapse
|
2
|
Treweeke AT, Maskrey BH, Hickson K, Miller JH, Leslie SJ, Megson IL. Iodixanol Has a Favourable Fibrinolytic Profile Compared to Iohexol in Cardiac Patients Undergoing Elective Angiography: A Double-Blind, Randomized, Parallel Group Study. PLoS One 2016; 11:e0147196. [PMID: 26784323 PMCID: PMC4718690 DOI: 10.1371/journal.pone.0147196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Accepted: 12/30/2015] [Indexed: 12/16/2022] Open
Abstract
Background There is no consensus and a limited evidence base for choice of contrast agents (CA) in angiography. This study evaluated the impact of iohexol and iodixanol CA on fibrinolytic factors (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1 [PAI-1]), as well as platelet-monocyte conjugates in cardiac patients undergoing elective angiography in a double-blind, randomised parallel group study. Methods Patients (men, 50–70 years old; n = 12) were randomised to receive either iohexol (Omnipaque; n = 6) or iodixanol (Visipaque; n = 6) during elective angiography at Raigmore Hospital, Inverness, UK. Arterial and venous blood samples were drawn prior to CA delivery and following angiography. Assessment of platelet-monocyte conjugation, t-PA and PAI-1 antigen and activity was conducted in samples pre- and post-angiography. Outcome Plasma t-PA antigen was depressed equally in the study groups after angiography, but there was a greater reduction in PAI-1 antigen in the group receiving iodixanol. These findings corresponded to a substantial reduction in t-PA activity in patients receiving iohexol, with no change in those receiving iodixanol (P = 0.023 between the CA groups). Both CAs caused a reduction in platelet-monocyte conjugation, with no difference between the groups. No adverse events were reported during the trial. Conclusion Avoiding reduced plasma t-PA activity might be an important consideration in choosing iodixanol over iohexol in patients at risk of thrombosis following angiography. The trial is registered on the ISRCTN register (ISRCTN51509735) and funded by the Coronary Thrombosis Trust and National Health Service (Highland) R&D Endowments. The funders had no influence over study design or reporting. Trial Registration Controlled-Trials.com ISRCTN51509735
Collapse
Affiliation(s)
- Andrew T. Treweeke
- Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, United Kingdom
| | - Benjamin H. Maskrey
- Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, United Kingdom
| | - Kirsty Hickson
- Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, United Kingdom
| | | | - Stephen J. Leslie
- Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, United Kingdom
- Cardiology, NHS Highland, Inverness, United Kingdom
- School of Nursing, Midwifery and Health, University of Stirling, Inverness, United Kingdom
| | - Ian L. Megson
- Department of Diabetes & Cardiovascular Science, University of the Highlands & Islands, Inverness, United Kingdom
- * E-mail:
| |
Collapse
|
3
|
Cicin I, Erdogan B, Gulsen E, Uzunoglu S, Sut N, Turkmen E, Kodaz H, Ustundag S. Incidence of contrast-induced nephropathy in hospitalised patients with cancer. Eur Radiol 2013; 24:184-90. [PMID: 24220752 DOI: 10.1007/s00330-013-2996-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Revised: 07/26/2013] [Accepted: 07/30/2013] [Indexed: 12/20/2022]
Abstract
OBJECTIVES To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with cancer. METHODS Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. RESULTS CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with hypertension (P = 0.044). CONCLUSIONS The incidence of CIN after CT in hospitalised oncological patients was 20 %. CIN developed 4.5-times more frequently in patients with cancer who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development. KEY POINTS • Contrast-induced nephropathy (CIN) is a concern for oncological patients undergoing CT. • CIN occurs more often when CT is performed <45 days after chemotherapy. • Hypertension and treatment with bevacizumab appear to be additional risk factors.
Collapse
Affiliation(s)
- Irfan Cicin
- Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey
| | | | | | | | | | | | | | | |
Collapse
|
4
|
|
5
|
Martinez J, Laskey WK, Wells C, Foghi A, Rohde S, Ricciardi M, Mobarak C. Proteomic Analysis of the Systemic Response to Radiographic Contrast Media. Clin Proteomics 2010. [DOI: 10.1007/s12014-010-9048-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Abstract
Introduction
Radiographic contrast media (RCM) have numerous effects on the hemostatic system, inflammatory pathways, and vascular endothelium. Given the increasing number of high-risk patients undergoing radiographic procedures, more information regarding the systemic effects of RCM is needed.
Methods
Blood samples prior to baseline, 4 and 24 h following elective coronary angiography in 10 patients, were subjected to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Data are presented as the ratio of the protein mass at 4 (iTRAQ4) and 24 h (iTRAQ24) compared to baseline. A ratio >1.0 and a ratio <1.0 indicate production and consumption, respectively, relative to baseline.
Results
In this sample, we identified 102 proteins with a confidence interval of ≥90%. Six proteins were identified at each time point in all patients. Of the proteins identified, apolipoprotein A-I, apolipoprotein A-II, complement C3, fibrinogen beta chain, immunoglobulin α, and prothrombin revealed an iTRAQ ratio <1.0 at 4 h when compared to baseline (all with p value <0.05) and a trend toward baseline levels at 24 h.
Conclusions
Systemic administration of RCM results in a variety of alterations to the proteome. Of interest, there is activation of the thrombotic and inflammatory pathways as well as an interaction with lipoprotein metabolism. These changes are most pronounced at 4 h but may persist through 24 h and may be of clinical relevance in patients at risk for thrombotic- and inflammatory-mediated consequences of atherosclerosis.
Collapse
|
6
|
Klein LW, Sheldon MW, Brinker J, Mixon TA, Skelding K, Strunk AO, Tommaso CL, Weiner B, Bailey SR, Uretsky B, Kern M, Laskey W. The use of radiographic contrast media during PCI: a focused review: a position statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2010; 74:728-46. [PMID: 19830793 DOI: 10.1002/ccd.22113] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Lloyd W Klein
- Rush Medical College & Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois 60657, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Fägerstam JP, Ostberg AK, Eriksson AC, Fransson SG, Whiss PA. Similar inhibition of platelet adhesion, P-selectin expression and plasma coagulation by ioversol, iodixanol and ioxaglate. Br J Radiol 2009; 83:401-10. [PMID: 19546176 DOI: 10.1259/bjr/71758045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Contrast media (CM) are reported to possess both prothrombotic and anticoagulant properties. The mechanisms are not clearly understood, and early reports are contradictory. To study the effects of CM on haemostasis, we analysed the ex vivo effects of ioversol and iodixanol on platelet adhesion and P-selectin expression, and the in vitro effects of ioversol, iodixanol and ioxaglate on platelet adhesion, P-selectin expression and plasma coagulation. A novel enzymatic assay was used to measure platelet adhesion to protein surfaces, and an enzyme-linked immunosorbent assay was used to measure platelet P-selectin surface expression. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were used to measure plasma coagulation. The ex vivo study consisted of blood from 27 outpatients administered ioversol and 9 patients administered iodixanol intravenously. Samples were collected before and 5 min after CM administration. Healthy donors were used for the in vitro studies on the effects of CM. The ex vivo study showed significantly (p<0.05) decreased platelet adhesion and P-selectin expression after administration of ioversol and iodixanol. Adhesion was more affected than P-selectin expression. The in vitro study showed that ioversol, iodixanol and ioxaglate significantly (p<0.05) and dose-dependently (beginning at 3 mg ml(-1)) decreased platelet adhesion and P-selectin expression. APTT and PT were significantly (p<0.01) prolonged at concentrations of 10 mg ml(-1) and 30 mg ml(-1), respectively. In conclusion, ioversol, iodixanol and ioxaglate inhibit platelet adhesion and P-selectin expression, as well as plasma coagulation. Platelets are more sensitive in relation to the inhibiting effect on plasma coagulation.
Collapse
Affiliation(s)
- J P Fägerstam
- Department of Medical and Health Sciences, Linköping University, Sweden
| | | | | | | | | |
Collapse
|
8
|
|
9
|
Hsieh YC, Liu TJ, Liang KW, Her HY, Lin WW, Wang KY, Chen YT, Ting CT, Lee WL. Iso-osmolar contrast medium better preserves short- and long-term renal function after cardiovascular catheterizations in patients with severe baseline renal insufficiency. Int J Cardiol 2006; 111:182-4. [PMID: 16624433 DOI: 10.1016/j.ijcard.2005.11.076] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2005] [Accepted: 11/15/2005] [Indexed: 10/24/2022]
Abstract
BACKGROUND Iso-osmolar iodixanol was shown to least affect very-short-term renal function. However, its short- and long-term renal effects after cardiovascular catheterizations in severe renal insufficiency remain unknown. METHODS Patients undergoing elective cardiovascular catheterizations and having pre-procedural serum creatinine (Scr) > or =2.5 mg/dl were prospectively studied. The results were compared to those of historical controls who received iopromide. RESULTS The iodixanol group included 27 patients, aged 73+/-1 years, and the case-matched control group consisted of another 27 patients, aged 71+/-1 years. The baseline Scr were 3.0+/-0.3 and 3.0+/-0.2 mg/dl respectively. Although the Scr at 3 months was similar, the Scr at 6 months was lower in the iodixanol group (2.7+/-0.3 vs 4.2+/-0.5 mg/dl, p = 0.017). The absolute and percentage increments in Scr at 3 months (0.0+/-0.2 vs 0.6+/-0.2 mg/dl, p = 0.014, and 1+/-4% vs 24+/-6%, p = 0.003, respectively) and 6 months (-0.3+/-0.2 vs 1.3+/-0.4 mg/dl, p = 0.001, and -10+/-5% vs 47+/-12%, p < 0.001, respectively) were lower in the iodixanol group. CONCLUSIONS Iodixanol better preserves short- and long-term renal outcomes in patients with severe baseline renal insufficiency.
Collapse
|
10
|
Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20:1542-50. [PMID: 16033768 DOI: 10.1093/ndt/gfh868] [Citation(s) in RCA: 114] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Esplugas E, Cequier A, Gomez-Hospital JA, Del Blanco BG, Jara F. Comparative tolerability of contrast media used for coronary interventions. Drug Saf 2003; 25:1079-98. [PMID: 12452733 DOI: 10.2165/00002018-200225150-00003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Radiographic contrast media (CM) are necessary to provide x-ray absorption of the bloodstream; all other observed effects need to be regarded as adverse. Four types of CM are currently used in diagnostic and interventional cardiology: ionic high-osmolar CM (HOCM), either ionic or non-ionic low-osmolar CM (LOCM), and non-ionic iso-osmolar CM (IOCM). Focusing on the potential cardiovascular effects caused by the CM, there is a clear difference between HOCM and the LOCM or IOCM. HOCM have a poorer profile due to a higher incidence of hypotension and electrophysiological effects. To prevent contrast-induced nephropathy, HOCM should be avoided and patients should receive the minimal dose of LOCM or IOCM with intravenous hydration before and after the procedure. Clinical hyperthyroidism has been detected after CM use, but the condition appears, ultimately, to be self-limited and to occur mainly in elderly patients. When assessing the need for a CM in terms of improved patient safety, preventing serious complications should be the major factor determining the choice. CM should not be selected on the basis of minor adverse effects since these are, ultimately, of low clinical relevance. Thrombotic events, in contrast, carry a high clinical relevance and we consider that these should be the main issue governing current choice. Ionic LOCM appear to have better profile than other CM with respect to interaction with platelet function and coagulation. In relation to thrombotic events in randomised clinical studies, ionic CM have been associated, mainly, with favourable and some neutral results compared with non-ionic agents. Only one trial indicated a more pronounced antithrombotic effect of the non-ionic IOCM relative to the ionic LOCM. The antithrombotic advantages of ionic over non-ionic LOCM are, in part, balanced by a greater frequency of minor adverse effects such as nausea, vomiting or cutaneous rashes. A matter of concern is the delayed adverse effects observed with non-ionic IOCM. However, severe and life-threatening reactions are exceptional and there are probably no significant differences between IOCM and LOCM whether ionic or non-ionic. However, in patients with known allergies, non-ionic CM are to be recommended. On the basis of the available pre-clinical and clinical data, the ionic LOCM or the non-ionic IOCM are the agents to be recommended in percutaneous coronary interventions because of their antithrombotic advantages over non-ionic LOCM.
Collapse
Affiliation(s)
- Enrique Esplugas
- Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat Barcelona, Spain.
| | | | | | | | | |
Collapse
|
12
|
Spitzer SG, Pindur G, Gerk U, Jung F. Influence of two non-ionic radiographic contrast media with different osmolalities on coagulation in invasive cardiology. A prospective, randomised comparative study. Acta Radiol 2002. [PMID: 12485262 DOI: 10.1034/j.1600-0455.2002.430615.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
PURPOSE To investigate the influence of two non-ionic radiographic contrast media with different osmolality on thrombocytic function and the plasmatic coagulation system. MATERIAL AND METHODS The study was carried out as a randomised, prospective, comparative study with two contrast media in a heart catheter laboratory. RESULTS Activating influences on platelet aggregation, procoagulatory or profibrinolytic functions or injury to the endothelium could be ruled out. Apparently, also differences in substance properties, such as the media's ionic character or osmolality had no demonstrable influence on the interaction with haemostatis and blood vessels. An adjuvant, antithrombotic therapy was carried out, which consisted of platelet aggregation inhibitors and heparins. CONCLUSION Our findings agree with the results of recent clinical trials, which demonstrated no relevant disadvantage of non-ionic contrast media as regards thrombotic complications.
Collapse
Affiliation(s)
- S G Spitzer
- Dresden Institute for Heart and Circulation Research, Dresden, Germany
| | | | | | | |
Collapse
|
13
|
Zhan X, Agrawal DK, Thorpe PE. Effect of iodinated contrast media on neutrophil adhesion to cultured endothelial cells. J Vasc Interv Radiol 1998; 9:808-16. [PMID: 9756071 DOI: 10.1016/s1051-0443(98)70396-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
PURPOSE To investigate the influence of contrast media (CM) on endothelial cells (ECs) with respect to cytotoxicity and to neutrophil adhesion. MATERIALS AND METHODS Human umbilical vein ECs were incubated with chromium-51-labeled human neutrophils in the presence of CM (diatrizoate, ioxaglate, iopamidol, and iodixanol) in three concentrations: 2, 20, and 50 mg I/mL. CM was compared with glucose solutions prepared from plain, buffered glucose solutions, iso-osmolar to the corresponding CM solution. Neutrophil adhesion to the EC monolayer, EC morphology, and cytotoxicity were evaluated. RESULTS The effect of CM on neutrophil adhesion was dependent on dose, with increased adhesion at low CM concentrations (2 and 20 mg I/mL) and decreased adhesion at high CM concentration (50 mg I/mL). The response was observed only if ECs and neutrophils were exposed to CM simultaneously in a shared environment. Glucose solutions with the same osmolarity did not show similar effect. Both diatrizoate and ioxaglate had a greater cytotoxic effect on ECs and neutrophils than did iodixanol and iopamidol. CONCLUSION The altered neutrophil adhesion to ECs may be due to CM-induced cytotoxicity or CM-induced EC activation because the glucose solutions did not cause a similar change at equal osmolality. The lack of cell death, combined with altered neutrophil adhesion implies modulation of cell adhesion molecules by CM. The results could be pertinent to the pathogenesis of peripheral vascular lesions and the endothelial response in immunosuppressed or septic patients receiving CM during imaging studies.
Collapse
Affiliation(s)
- X Zhan
- Department of Radiology, Creighton University Medical Center, Omaha, NE 68131, USA
| | | | | |
Collapse
|